These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 22768914)
1. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Dreaden EC; Gryder BE; Austin LA; Tene Defo BA; Hayden SC; Pi M; Quarles LD; Oyelere AK; El-Sayed MA Bioconjug Chem; 2012 Aug; 23(8):1507-12. PubMed ID: 22768914 [TBL] [Abstract][Full Text] [Related]
2. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Munuganti RS; Hassona MD; Leblanc E; Frewin K; Singh K; Ma D; Ban F; Hsing M; Adomat H; Lallous N; Andre C; Jonadass JP; Zoubeidi A; Young RN; Guns ET; Rennie PS; Cherkasov A Chem Biol; 2014 Nov; 21(11):1476-85. PubMed ID: 25459660 [TBL] [Abstract][Full Text] [Related]
3. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Thangavel C; Perepelyuk M; Boopathi E; Liu Y; Polischak S; Deshpande DA; Rafiq K; Dicker AP; Knudsen KE; Shoyele SA; Den RB Mol Pharm; 2018 May; 15(5):1778-1790. PubMed ID: 29616555 [TBL] [Abstract][Full Text] [Related]
4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
5. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525 [TBL] [Abstract][Full Text] [Related]
6. Antiandrogens in prostate cancer. Reid P; Kantoff P; Oh W Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479 [TBL] [Abstract][Full Text] [Related]
7. Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation. Yu S; Jia L; Zhang Y; Wu D; Xu Z; Ng CF; To KK; Huang Y; Chan FL Cancer Lett; 2013 Jan; 328(1):83-94. PubMed ID: 22995070 [TBL] [Abstract][Full Text] [Related]
8. Antiandrogens in prostate cancer endocrine therapy. Culig Z; Bartsch G; Hobisch A Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720 [TBL] [Abstract][Full Text] [Related]
9. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Gaur S; Gross ME; Liao CP; Qian B; Shih JC Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539 [TBL] [Abstract][Full Text] [Related]